{"type":"trials","record":{"id":86981,"source_id":"isrctn","external_id":"ISRCTN38641780","title":"A study to compare JNJ-81201887 to a sham procedure for the treatment of geographic atrophy secondary to age-related macular degeneration","brief_summary":"Primary objective: To assess the change in growth of geographic atrophy (GA) lesions in the eyes treated with JNJ-81201887 compared to sham control. Secondary objectives: 1. To assess effect of JNJ-81201887 on low luminance visual acuity (LLVA). 2. To assess effect of JNJ-81201887 on visual function and retinal function. 3. To assess effect of JNJ-81201887 on best corrected visual acuity (BCVA). 4. To assess effect of JNJ-81201887 on functional reading independence and patient reported outcomes (PROs)","overall_status":"Completed","phases":["Phase II"],"study_type":"Interventional","sponsor":"Janssen (Netherlands)","enrollment":305,"countries":["United Kingdom","England","Argentina","Australia","Belgium","Brazil","Canada","Denmark","Germany","Hungary","Italy","Mexico","Netherlands","Poland","Portugal","Spain","Sweden","Switzerland","Türkiye","Czech Republic","United States of America"],"start_date":"2023-03-06","completion_date":"2026-02-23","last_update_date":"2026-03-17","source_url":"https://www.isrctn.com/ISRCTN38641780","editorial_summary":"A registered Phase II study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:28.783517+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN38641780; retrieved 2026-09-25","interventions":["JNJ-81201887 (AAVCAGsCD59)","Biological/Vaccine"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Current primary outcome measure as of 27/08/2024: Change from baseline in square root of geographic atrophy (GA) lesion…","Current secondary outcome measures as of 27/08/2024: 1. Change From Baseline in Low Luminance Visual Acuity (LLVA) at M…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Geographic atrophy, secondary to age-related macular degeneration","Current interventions as of 29/05/2025: After the screening, participants will be randomly assigned to one of the three…","JNJ-81201887 (AAVCAGsCD59)","Biological/Vaccine"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn38641780","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-03-06 to 2026-02-23","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.561Z","intervention":["JNJ-81201887 (AAVCAGsCD59)","Biological/Vaccine"],"participants":305,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase II","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Current primary outcome measure as of 27/08/2024: Change from baseline in square root of geographic atrophy (GA) lesion…","Current secondary outcome measures as of 27/08/2024: 1. Change From Baseline in Low Luminance Visual Acuity (LLVA) at M…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86981","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}